Tech Company Inital Public Offerings
PhaseBio Pharmaceuticals IPO
Headquartered in Malvern, PhaseBio Pharmaceuticals is now a public company.
Transaction Overview
Company Name
Announced On
10/17/2018
Transaction Type
IPO
Amount
$46,000,000
Proceeds Purpose
Proceeds will be used as follows: approximately $37.0 million to $39.0 million to advance PB2452; approximately $11.0 million to $13.0 million to advance PB1046; approximately $12.0 million to $14.0 million to fund development of our ELP technology and preclinical programs; and the remainder for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Great Valley Pkwy. 30
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Not Recorded
Overview
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), located in Malvern, PA, is a development stage, privately held protein engineering company focused on developing the next generation of biopharmaceuticals.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonathan Mow
Chief Financial Officer
John Sharp
Chief Medical Officer
John Lee
VP - Bus. Development
Susan Arnold
VP - Bus. Development
Michael York
VP - R & D
James Ballance
Browse more venture capital transactions:
Prev: 10/17/2018: Hubb venture capital transaction
Next: 10/17/2018: Velicept Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs